Intravenous Secukinumab Demonstrates Long-Term Safety and Ef

Treatment with IV SEC demonstrated safety and efficacy through 52 weeks among adult patients with active axSpA.

Related Keywords

California , United States , San Diego , , American College Of Rheumatology , American College , Ankylosing Spondylitis Disease Activity Score , Bath Ankylosing Spondylitis Functional Index , Short Form , Component Summary ,